By AuntMinnie.com staff writers

August 26, 2009 -- Ultrasound imaging technology developer Targeson of La Jolla, CA, has introduced Visistar Integrin, a targeted ultrasound contrast agent for use in preclinical drug discovery and basic science research.

The microbubble contrast agent bears a covalently coupled peptide and is designed to selectively bind alphavbeta3 integrin on the vascular endothelial surface. Alphavbeta3 integrin is a biomarker of angiogenesis expressed on activated blood vessels.

Targeson said the contrast agent could be useful for investigating the cellular and molecular mechanisms of angiogenesis, molecular imaging of alphavbeta3 integrin expression, and evaluating anticancer therapies.

Targeson debuts US contrast agent, August 11, 2009

Copyright © 2009 AuntMinnie.com

 

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: